New Haven Neighborhood

CURE Cookout Draws Biotech Crowd to Branford
Back by popular demand,

the CURE summer biotech cookout was held again this year at the Owenego Inn in Branford.

More than 175 employees and friends of CURE member organizations registered for the July 17 event, playing the DNA Game, sampling the hot and cold buffet, and networking in the sunshine along the beautiful Connecticut shoreline.
For the full story

CURE Member News Digest
454 Life Sciences reports Neanderthal genome sequencing
Achillion CEO cites Q2 progress
Alexion announces new patent
Applied Spine device implanted in local man
Bayer HealthCare cites Nexavar® progress
Boehringer Ingelheim reports Aptivus® approval
Bristol-Myers Squibb offers ReSEARCH program to students
Cantor Colburn newsletter reviews trademark case
Connecticut Innovations named to top 100 list
CuraGen pleased with Q2 progress
Danbury Hospital heart center offers newest stents
GlaxoSmithKline reports results on HuMax-CD20®
Hartford Hospital welcomes electrophysiology head
HistoRx names diagnostic operations head
Ipsogen wins CE marking for JAK2 test
Johnson & Johnson cites VisiCare Institute™ role at Olympics
MannKind to host plant dedication in Danbury
NanoViricides sees efficacy for its EKC-Cide™ for eyes
Neurogen focuses of Phase 2 drug
Pfizer promotes Cerenia™ drug for dogs
PhRMA dreports on mental illness drugs
Purdue Pharma unveils tookkit for pain management
Quinnipiac University to offer online OT courses
Rib-X names George Milne executive chairman
Triumvirate Environmental acquires Enviro-Safe branches
UConn researchers report in nanotechnology publication
Vion to test Cloretazine® with Dutch group
Yale identifies West Nile genes
For the full story

"Let Me Down Easy" By Anna Deveare Smith

Event Chairmen Paul Pescatello, President, CURE David Scheer, President, Scheer & Co SIGN UP EARLY Supper and Arts Outing at Long Wharf for Connecticut's pharma and biotech communities Wednesday, January 30, 2008 Supper: 5 - 6:45 pm Theater Curtain: 7 pm "Let Me Down Easy" by Tony-award winning playwright and actress Anna Deveare Smith Winner of a MacArthur Foundation "genius" fellowship and hailed by Newsweek as "the most exciting individual in American theatre" This one-woman show about the resilience and fragility of the human body debuted at Yale Medical School where Smith was a visiting professor. at New Haven's nationally known Long Wharf Theatre This is an exciting opportunity to see a play before it heads for New York City. Bring your spouse. Share this with colleagues and friends. Before the show, join us for supper at Leon's (formerly the Rusty Scupper) Hear about the play from the producers. Learn about another New Haven arts jewel, The New Haven Symphony. Seats are limited. They will be distributed first come, first served. SIGN UP EARLY Click here for directions to the theater Click here for directions to the restaurant Cost for employees of CURE members and their guests (per person): $45 Theater only. $68 Theater and Dinner Cost for non members (per person): $50 Theater only. $110 per person. Click here to find out if your company is a CURE member All profits go to DEVELOPING WORLD CURES. This new New Haven non-profit is dedicated to developing medicines, assays and devices to treat diseases prevelant in the developing world for which existing treatments are not effective or suitable.

CURE & YALE University: Yale BioHaven Enterprenurship

Tuesday, February 12, 2008 Rib-X Pharmaceuticals, Inc. Followed by networking, refreshments & wine bar Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. Since its inception in 2001, Rib-X has established a portfolio of development and discovery-stage compounds that address various segments in the diverse antibiotic marketplace, including RX-3341, a broad spectrum quinolone antibiotic which will soon enter Phase 3 studies as an IV agent and RX-1741, an oxazolidinone antibiotic now in two Phase 2 studies as an oral agent. Many classical antibiotics work by inhibiting the function of the ribosome. A key competitive advantage for Rib-X is its proprietary access to the high-resolution crystal structure of the ribosome, a molecule which is essential for the viability of all bacterial pathogens and the target of numerous valuable antibiotics. Rib-X's research goal is to use chemical and physical information from the three-dimensional structure of the ribosome to design proprietary classes of antibacterial agents that have activity against newly emerging multiple antibiotic-resistant microorganisms. Structural and computational data about how ligands block the function of this complex molecular machine are being used to prime parallel lead optimization programs focused on new chemistry ideas about the multiple binding domains or drug targets within the ribosome. The scope of the Rib-X structure based design process will enable the Company to fully exploit the chemistry of the ribosome and build a pipeline of diverse products and as a result a sustainable franchise. Rib-X raised $50 million in a Series C Preferred Stock financing announced in June of 2006. The round was led by existing investor Warburg Pincus, the global private equity investment firm. That round of financing brought the total amount raised by the company to $123 million. Speakers Susan Froshauer, Ph.D. President & Chief Executive Officer, Rib-X Pharmaceuticals, Inc. Erin Duffy, Ph.D. Vice President, Structure Based Drug Design, Rib-X Pharmaceuticals, Inc. Tuesday, February 12, 2008 3:30 P.M. Registration 4:00 P.M. Seminar 5:00 P.M. Networking, Refreshments & Wine Bar Location The Anlyan Center auditorium, Yale Medical School. Directions & Parking: http://info.med.yale.edu/maps/cab.html RSVP Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209. Mark Your Calendar The next seminar in the series, on March 19, 2008, features Optherion, Inc. Download a brochure of the complete 2007-2008 series here. Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers. Also sponsored by Elm Street Ventures. Presented by CURE and the Yale Office of Cooperative Research. Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society. Published by Connecticut United for Research Excellence Copyright © 2008 Connecticut United for Research Excellence. All rights reserved. Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org TELL A FRIEND

Powered by IMN™ this e-mail was sent to drmuni From Connecticut United for Research Excellence, 300 George Street, New Haven, CT 06511 USA

Connecticut-BioTech: CURE Holiday Celebration in New Haven

Here is a Holiday celebration for scientists, Pharmaceutical industry folks and Biotech fellows.

Date: December 4, 2oo7

Goerge Street, New Haven-CT